Complexes of Trypanosoma cruzi Sterol 14 -Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease: STRUCTURAL BASIS FOR PATHOGEN SELECTIVITY
about
Expanding the Binding Envelope of CYP51 Inhibitors TargetingTrypanosoma cruziwith 4-Aminopyridyl-Based Sulfonamide DerivativesStructural Basis for Rational Design of Inhibitors Targeting Trypanosoma cruzi Sterol 14α-Demethylase: Two Regions of the Enzyme Molecule Potentiate Its Inhibition4-Aminopyridyl-Based CYP51 Inhibitors as Anti- Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo PotencyThe Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases-Part III: In-Silico Molecular Docking InvestigationsMachine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug DiscoveryDevelopment of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas DiseaseNew compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibitionDrug strategies targeting CYP51 in neglected tropical diseasesBinding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.Interactions of antiparasitic sterols with sterol 14α-demethylase (CYP51) of human pathogensDevelopment and application of a sensitive, phenotypic, high-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotesStructure-Functional Characterization of Cytochrome P450 Sterol 14α-Demethylase (CYP51B) from Aspergillus fumigatus and Molecular Basis for the Development of Antifungal Drugs.VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis.Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.Chagas disease drug discovery: toward a new era.Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis.Crystal Structure of the New Investigational Drug Candidate VT-1598 in Complex with Aspergillus fumigatus Sterol 14α-Demethylase Provides Insights into Its Broad-Spectrum Antifungal Activity.Efficient electrochemical N-alkylation of N-boc-protected 4-aminopyridines: towards new biologically active compounds.In vitro drug susceptibility of two strains of the wildlife trypanosome, Trypanosoma copemani: A comparison with Trypanosoma cruziHuman sterol 14α-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design.Antitrypanosomal and antileishmanial activity of prenyl-1,2,3-triazoles.3-pyridyl inhibitors with novel activity against Trypanosoma cruzi reveal in vitro profiles can aid prediction of putative cytochrome P450 inhibition.
P2860
Q27683570-50E27B16-02EE-4566-99DB-D481392ED57DQ27684715-D77AFB67-E0DA-4F2D-A81C-5A596A3D52E1Q27684956-CE0F8DA8-42E6-42D3-9421-8638C5BD50E4Q28066944-FEC84C85-9596-4EDA-8DB6-EC2C308A53A7Q28545842-DF87B5BC-480A-46FF-A2C3-6F3B199C05C3Q28548320-BEE761BB-14B7-4716-8D01-2EBCC6AA7B03Q30417002-40377A79-9BD0-4743-A790-31C46AF01D69Q34614864-239F49B5-5D81-440E-806D-9D70D98EB446Q34622554-3A548E45-7FE2-4278-AAEF-CED980039DE2Q34701325-95A0C041-02BC-4DC3-9169-CC2597D919E2Q35541487-31C9E6B2-364D-471C-B792-EE3BEDFED4E7Q36000826-EE556659-58D6-4BCF-8442-265AED9EAA41Q36093075-EAB5F05F-44AB-4C68-9CED-8164EBF8721AQ36148993-8DB29A23-113C-4701-B81B-115E552357A8Q36571788-C0F35919-8CBC-4007-83DA-0E3A17BC21C6Q37401820-7968431A-2B00-4B5A-8F84-647CC3F9299BQ37449720-A4A160A6-63B2-4B2D-BE0E-785251997CACQ37732551-9DFDE725-C1FA-497C-BFC9-3E0893CA3F11Q38253281-D3A3D3D9-8A21-4B27-B2CD-C915FD8A0E2CQ38750944-E40959C2-3313-417E-B778-7C9F0856AD7AQ38810307-FC48DA37-FC6E-42DC-8AB1-C634049D538BQ40150000-DFF8AE7C-2F34-43D6-B026-F94DD39E656BQ40389286-A0FC94E8-DCD6-46C7-B7B4-193E79C6C2F5Q42266154-2D51B80B-4C88-4727-B4F0-A2DCB22A92CEQ49376507-6BD00195-017E-4170-89BB-FA771DAD0424Q52646076-DFD540F1-6450-47BF-9B78-BB50B0382622
P2860
Complexes of Trypanosoma cruzi Sterol 14 -Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease: STRUCTURAL BASIS FOR PATHOGEN SELECTIVITY
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Complexes of Trypanosoma cruzi ...... BASIS FOR PATHOGEN SELECTIVITY
@ast
Complexes of Trypanosoma cruzi ...... BASIS FOR PATHOGEN SELECTIVITY
@en
Complexes of Trypanosoma cruzi ...... BASIS FOR PATHOGEN SELECTIVITY
@nl
type
label
Complexes of Trypanosoma cruzi ...... BASIS FOR PATHOGEN SELECTIVITY
@ast
Complexes of Trypanosoma cruzi ...... BASIS FOR PATHOGEN SELECTIVITY
@en
Complexes of Trypanosoma cruzi ...... BASIS FOR PATHOGEN SELECTIVITY
@nl
prefLabel
Complexes of Trypanosoma cruzi ...... BASIS FOR PATHOGEN SELECTIVITY
@ast
Complexes of Trypanosoma cruzi ...... BASIS FOR PATHOGEN SELECTIVITY
@en
Complexes of Trypanosoma cruzi ...... BASIS FOR PATHOGEN SELECTIVITY
@nl
P2093
P2860
P921
P356
P1476
Complexes of Trypanosoma cruzi ...... BASIS FOR PATHOGEN SELECTIVITY
@en
P2093
Catherine J Perez
Eric Chatelain
Galina I Lepesheva
Jason H Chaplin
Martine Keenan
Michael R Waterman
Paul W Alexander
Susan A Charman
Tatiana Y Hargrove
P2860
P304
P356
10.1074/JBC.M113.497990
P407
P577
2013-11-01T00:00:00Z